A low-emulsifier-containing diet led to a threefold increased likelihood of improvement in symptoms of Crohn’s disease ...

Milestone payment of $10 million triggered under the global license agreement with TakedaLEXINGTON, Mass., July 17, 2025 ...

Researchers have found in a 3-year phase 3 trial that palopegteriparatide (TransCon PTH) showed sustained improvements in ...

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

IRVINE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the TrilogyTM Transcatheter Heart Valve (THV) System, today announced that patient ...

Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company ...

A trial testing a nerve-sparing (NeuroSAFE) technique in radical prostatectomy may improve patient-reported outcomes.

The results "underscore that clinicians should be aware of CBD-associated hepatoxic effects and screen patients with elevated ...

Hyderabad: Suven Life Sciences has announced that the first patient has been randomized in its Phase-2b clinical trial ...

This randomized, double-masked, placebo-controlled, Phase 2 Proof-of-Concept trial of urcosimod to treat NCP was conducted at a single trial site at Tufts Medical Center in Boston, MA, with Pedram ...

Vibration therapy eases fatigue and improves motor and cognitive outcomes in MS, outperforming standard physical exercise ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that patient enrollment has begun in the ARTIST study, an RCT evaluating ...